• June 3-6, 2024
  • San Diego Convention Center, California

Sessions

Loading

Praetego Inc

Monday, June 03, 2024
CP
CNS/Neurological
Praetego is pioneering a groundbreaking class of drugs known as Amadorins. Our mission is to protect patients from debilitating age-related neurodegeneration, with a focus on Alzheimer’s disease. Praetego is committed to limiting Alzheimer's disease, thereby enhancing the overall aging experience. With a successful pre-IND meeting completed, our lead, PTG-630, is ready for IND-enabling, and aiming for clinic within 12 months. Our approach centers on mitigating the impact of Advanced Glycation End-products (AGEs), commonly referred to as glycotoxins, generated during the essential process of glucose metabolism. AGEs wreak havoc on the body as it ages. These compounds drive aberrant protein aggregation, chronic inflammation, oxidative stress, and, ultimately, organ damage. Praetego's Amadorins act as a powerful counterforce, inhibiting the formation of AGEs, offering an early deterrent to age-related neurodegeneration and Alzheimer’s disease.
Praetego Inc
Company Website: http://www.praetego.com
Lead Product in Development: PTG-630
Number Of Unlicensed Products (For Which You Are Seeking Partners): 2

Company HQ City

Durham

Company HQ State

NC

Company HQ Country

United States

CEO/Top Company Official

Pepper Landson

Development Phase of Primary Product

Pre-Clinical
Back to Session List

BIO DOUBLE HELIX SPONSORS

Thanks to our sponsors for supporting our mission to drive a revolution to cure patients, protect our climate, and nourish humanity.

Loading

BIO HELIX SPONSORS